New Methylation Profiling Assay for Liquid Biopsy

mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.

Original reporting
Published Nov 12, 2026, 5:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
New Methylation Profiling Assay for Liquid Biopsy — source image
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The collaboration introduces a new research tool that could enhance early‑stage cancer monitoring but remains pre‑clinical.

02

Market read

Introduces a niche research assay that may incrementally benefit Thermo Fisher and Biodesix, with limited immediate market move.

03

What to watch

Regulatory clearance timelines and the need for clinical validation could delay revenue impact.

Relevance 6/10Novelty 6/10Timing: today

Background

Thermo Fisher and mDETECT partner to combine methylation enrichment with Ion AmpliSeq HD technology for lung cancer cfDNA analysis.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher Scientific announced a new methylation profiling liquid biopsy assay, the first public disclosure of this product.

Expected impact

likely slight upward pressure as investors price in incremental revenue from the assay.

Evidence & confidence

The assay targets a niche research market; impact depends on adoption by partners like Biodesix.

$BDSXNeutralMedium confidence
Context

Biodesix will evaluate the new Thermo Fisher methylation assay in collaboration, marking its first involvement with this technology.

Expected impact

possible modest upside as the partnership could expand Biodesix's service offerings.

Evidence & confidence

Biodesix gains early access to a novel assay, but commercial impact is uncertain at this stage.

Market effects

Could stimulate interest in liquid biopsy and methylation‑based diagnostics across the biotech sector.

Primarily U.S. research market; limited immediate global effect.

Modest, as the assay is research‑focused rather than a commercial diagnostic.

Counterpoint

The assay may face slow adoption due to competition from existing ctDNA platforms and uncertain reimbursement pathways.

Key entities

  • Thermo Fisher Scientific

    US‑listed provider of scientific instruments and reagents.

  • mDETECT

    Private firm specializing in methylation‑based diagnostics.

  • Biodesix

    US‑listed clinical diagnostics company evaluating the assay.

Related articles

High

Biodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%

Biodesix Inc reported Q3FY26 revenue of $24.0M, missing estimates of $27.44M. Shares fell 29.44% after-hours. Full-year guidance was reduced to $101M-$103M from $108M-$114M. Revenue growth was 10% YoY, but test volume growth was offset by lower revenue per test. Gross margin remained at 81%, and net loss improved 8% YoY to $8.0M.

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.